{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:41:46Z","timestamp":1781703706929,"version":"3.54.5"},"reference-count":47,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:00:00Z","timestamp":1760140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"CERCA Programme"},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Malignant pericardial effusion (MPE) is a life-threatening condition in patients with cancer, with common recurrences after simple pericardiocentesis. Consequently, the intrapericardial instillation of sclerosing or cytotoxic agents has been explored, with limited evidence from small studies with different methodologies. We undertook an observational, retrospective, single-centre study, including all patients diagnosed with a solid neoplasm and clinically significant and\/or recurrent, cytology-confirmed MPE, treated with Intrapericardial Instillation of Cisplatin (IPIC), between 2009 and 2022. Patients with hematological malignancies were excluded. The procedure followed a multidisciplinary approach and a standardized protocol. Variables collected included baseline patient characteristics, neoplasm details, MPE impact, adverse events (AEs) from procedures (pericardiocentesis and IPIC) and outcomes (time to MPE recurrence and survival). This study adhered to the STROBE guidelines. A total of 41 patients were included, 51% female, with a median age of 61 (51\u201369) years. Non-small cell lung cancer (NSCLC) was the predominant primary tumour (78%) and in 44% of the cohort, MPE was identified at cancer diagnosis. Most patients (90.2%) presented symptoms related to MPE at diagnosis, and 88% had cardiac tamponade on echocardiography. IPIC was administered a median of four times. IPIC-related AEs occurred in 10 patients (24.4%), with transient atrial fibrillation (AF) being the most frequent one. Two patients (4.9%) experienced MPE recurrence within 30 days after IPIC. The median survival time from MPE diagnosis was 161 days (5.4 months; IQR 73\u2013455 days). IPIC appears to be a feasible, effective and safe option for reducing the risk of MPE recurrence, mainly in NSCLC.<\/jats:p>","DOI":"10.3390\/curroncol32100568","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T08:34:26Z","timestamp":1760517266000},"page":"568","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Retrospective Cohort Study of Intrapericardial Cisplatin for Risk Reduction of Malignant Pericardial Effusion Recurrence"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-7767","authenticated-orcid":false,"given":"Francisco Javier","family":"Mu\u00f1oz-Carrillo","sequence":"first","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana Maribel","family":"Reyes","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Pes\u00e1ntez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Carrera","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9093-3642","authenticated-orcid":false,"given":"Enric","family":"Cascos","sequence":"additional","affiliation":[{"name":"Cardiology Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6118-8970","authenticated-orcid":false,"given":"Pedro","family":"Castro","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2912-3357","authenticated-orcid":false,"given":"Sara","family":"Fern\u00e1ndez-M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carme","family":"Font","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gonz\u00e1lez-Aguado","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Grafi\u00e1","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc\u00eda","family":"Llavata","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Monge-Escart\u00edn","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-5811","authenticated-orcid":false,"given":"Joan","family":"Padrosa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noem\u00ed","family":"Reguart","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3502-5999","authenticated-orcid":false,"given":"Adri\u00e1n","family":"T\u00e9llez","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-5856","authenticated-orcid":false,"given":"Albert","family":"Tuca","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Chair of Palliative Care, Barcelona University, 08036 Barcelona, Spain"},{"name":"EAPS Fundaci\u00f3 La Caixa, 08019 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Viladot","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3838-0809","authenticated-orcid":false,"given":"Carles","family":"Zamora-Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9258-2623","authenticated-orcid":false,"given":"Patr\u00edcia","family":"Amor\u00f3s-Reboredo","sequence":"additional","affiliation":[{"name":"Pharmacy Department and Digital Impulse, Strategy and Transformation Area, Hospital de Sant Pau, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8486-5404","authenticated-orcid":false,"given":"Javier","family":"Marco-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department Hospital Clinic de Barcelona and Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, 08036 Barcelona, Spain"},{"name":"Medical Intensive Care Unit, Internal Medicine Department, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1159\/000348559","article-title":"Malignant pericardial effusion","volume":"124","author":"Burazor","year":"2013","journal-title":"Cardiology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/heartjnl-2019-315852","article-title":"Pericardial diseases in patients with cancer: Contemporary prevalence, management and outcomes","volume":"106","author":"Imazio","year":"2020","journal-title":"Heart"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pcad.2010.06.003","article-title":"Evaluation and management of pericardial effusion in patients with neoplastic disease","volume":"53","author":"Maisch","year":"2010","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0025-6196(11)65028-3","article-title":"Outcomes of primary and secondary treatment of pericardial effusion in patients with malignancy","volume":"75","author":"Tsang","year":"2000","journal-title":"Mayo Clin. Proc."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1200\/JCO.2005.00.745","article-title":"Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion","volume":"23","author":"Gornik","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_6","first-page":"e33123","article-title":"Cardiac Tamponade in Patients with Breast Cancer: A Systematic Review","volume":"14","author":"Ilerhunmwuwa","year":"2022","journal-title":"Cureus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1093\/eurheartj\/ehv318","article-title":"2015 ESC Guidelines for the diagnosis and management of pericardial diseases","volume":"36","author":"Adler","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_8","unstructured":"European Society of Medical Oncology (ESMO) (2016). ESMO Handbook of Oncological Emergencies, ESMO. [2nd ed.]."},{"key":"ref_9","first-page":"947","article-title":"Evaluation and management of cancer patients presenting with acute cardiovascular disease: A Consensus Document of the Acute CardioVascular Care (ACVC) association and the ESC council of Cardio-Oncology\u2014Part 1: Acute coronary syndromes and acute pericardial diseases","volume":"10","author":"Gevaert","year":"2021","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.pcad.2016.12.009","article-title":"Pericardial Effusions: Causes, Diagnosis, and Management","volume":"59","author":"Vakamudi","year":"2017","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Dybowska, M., Szturmowicz, M., B\u0142asi\u0144ska, K., Gatarek, J., Augustynowicz-Kope\u0107, E., Langfort, R., Kuca, P., and Tomkowski, W. (2022). Large Pericardial Effusion\u2014Diagnostic and Therapeutic Options, with a Special Attention to the Role of Prolonged Pericardial Fluid Drainage. Diagnostics, 12.","DOI":"10.3390\/diagnostics12061453"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.amjcard.2015.11.023","article-title":"Cause and Long-Term Outcome of Cardiac Tamponade","volume":"117","author":"Vivas","year":"2016","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10741-012-9335-x","article-title":"Pericardial syndromes: An update after the ESC guidelines 2004","volume":"18","author":"Kanjuh","year":"2013","journal-title":"Heart Fail. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1378\/chest.126.5.1412","article-title":"Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa","volume":"126","author":"Martinoni","year":"2004","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/heartjnl-2015-307907","article-title":"Systematic review of percutaneous interventions for malignant pericardial effusion","volume":"101","author":"Virk","year":"2015","journal-title":"Heart"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/icvts\/ivu267","article-title":"Palliative treatment for symptomatic malignant pericardial effusion","volume":"19","author":"Jama","year":"2014","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1080\/17843286.2020.1790180","article-title":"Malignant cardiac tamponade: Safety and efficacy of intrapericardial bleomycin instillation","volume":"77","author":"Defruyt","year":"2020","journal-title":"Acta Clin. Belg."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0002-9149(00)00937-1","article-title":"Malignant cardiac tamponade in women with breast cancer treated by pericardiocentesis and intrapericardial administration of triethylenethiophosphoramide (thiotepa)","volume":"86","author":"Bishiniotis","year":"2000","journal-title":"Am. J. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/14779072.2015.1025754","article-title":"2015 update on the diagnosis and management of neoplastic pericardial disease","volume":"13","author":"Lestuzzi","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-019-03897-0","article-title":"Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: A pilot study","volume":"84","author":"Kotake","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_21","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS) (2023, March 24). Cisplatino: Ficha T\u00e9cnica. Available online: https:\/\/cima.aemps.es\/cima\/pdfs\/es\/ft\/62107\/FT_62107.pdf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/euhj.2002.3328","article-title":"Neoplastic pericardial effusion: Efficacy and safety of intrapericardial treatment with cisplatin","volume":"23","author":"Maisch","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_23","first-page":"53","article-title":"Evaluation of intrapericardial cisplatin administration in cases with recurrent malignant pericardial effusion and cardiac tamponade","volume":"12","author":"Tomkowski","year":"2004","journal-title":"Support. Care Cancer"},{"key":"ref_24","first-page":"324","article-title":"Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade","volume":"46","author":"Bischiniotis","year":"2005","journal-title":"Hell. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.lungcan.2010.10.013","article-title":"Neoplastic pericardial disease in lung cancer: Impact on outcomes of different treatment strategies. A multicenter study","volume":"72","author":"Lestuzzi","year":"2011","journal-title":"Lung Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00570493","article-title":"Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion","volume":"20","author":"Figoli","year":"1987","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1093\/eurheartj\/ehs372","article-title":"Management of pericardial effusion","volume":"34","author":"Imazio","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6604866","article-title":"A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)","volume":"100","author":"Kunitoh","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.bulcan.2020.04.010","article-title":"Intrapericardial bleomycin instillation prevent recurrence of malignant pericardial effusions: Series of 46 cases and comprehensive literature review","volume":"107","author":"Lambert","year":"2020","journal-title":"Bull. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"18211","DOI":"10.1002\/cam4.6404","article-title":"Effects of intrapericardial administration after catheter drainage on malignant pericardial effusion in non-small cell lung cancer: A real-world study","volume":"12","author":"Wei","year":"2023","journal-title":"Cancer Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1002\/cncr.27409","article-title":"Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer","volume":"118","author":"Doebele","year":"2012","journal-title":"Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.21037\/tlcr-20-1152","article-title":"Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: Present and ongoing strategies\u2014A narrative review","volume":"10","author":"Fallet","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_33","first-page":"1579","article-title":"Introducing a new entity: Chemotherapy-induced arrhythmia","volume":"11","author":"Guglin","year":"2009","journal-title":"EP Eur."},{"key":"ref_34","first-page":"S279","article-title":"Local chemotherapy with cisplatin in non small lung cancer patients and malignant cardiac tamponade","volume":"35","author":"Lafaras","year":"2009","journal-title":"Intensive Care Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.1984.2.6.631","article-title":"Intrapericardial tetracycline sclerosis in the treatment of malignant pericardial effusion: An analysis of thirty-three cases","volume":"2","author":"Davis","year":"1984","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/0002-9149(87)90411-5","article-title":"Medical management of malignant pericardial effusion by tetracycline sclerosis","volume":"60","author":"Shepherd","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e19687","DOI":"10.1200\/jco.2010.28.15_suppl.e19687","article-title":"Efficacy and safety of intrapericardial bleomycin for malignant pericardial effusion","volume":"28","author":"Moya","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/JTO.0b013e31802c8260","article-title":"Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: A multi-institutional phase II trial","volume":"2","author":"Maruyama","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1136\/thx.49.6.594","article-title":"Ultrasound guided pericardial drainage and intrapericardial instillation of mitomycin C for malignant pericardial effusion","volume":"49","author":"Lee","year":"1994","journal-title":"Thorax"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000218465","article-title":"Intrapericardial Application of Mitoxantrone for Treatment of Malignant Pericardial Effusion","volume":"17","author":"Lentzsch","year":"1994","journal-title":"Oncol. Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000069833","article-title":"Intrapericardial Instillation of Mitoxantrone in Palliative Therapy of Malignant Pericardial Effusion","volume":"26","author":"Musch","year":"2003","journal-title":"Oncol. Res. Treat."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3748\/wjg.v16.i6.740","article-title":"Pericardiocentesis with cisplatin for malignant pericardial effusion and tamponade","volume":"16","author":"Oida","year":"2010","journal-title":"World J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1200\/JCO.1998.16.7.2371","article-title":"Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: An active and well-tolerated regimen","volume":"16","author":"Colleoni","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jjco\/hyi019","article-title":"Management of Malignant Pericardial Effusion with Instillation of Mitomycin C in Non-small Cell Lung Cancer","volume":"35","author":"Kaira","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"17112","DOI":"10.1002\/cam4.6360","article-title":"Real-world treatment outcomes of medicines used in special situations (off-label and compassionate use) in oncology and hematology: A retrospective study from a comprehensive cancer institution","volume":"12","author":"Fontanals","year":"2023","journal-title":"Cancer Med."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Zaij, S., Pereira Maia, K., Leguelinel-Blache, G., Roux-Marson, C., Kinowski, J.M., and Richard, H. (2023). Intervention of pharmacist included in multidisciplinary team to reduce adverse drug event: A qualitative systematic review. BMC Health Serv. Res., 23.","DOI":"10.1186\/s12913-023-09512-6"},{"key":"ref_47","first-page":"100580","article-title":"Does Multidisciplinary Team Management Improve Clinical Outcomes in NSCLC? A Systematic Review with Meta-Analysis","volume":"4","author":"Souza","year":"2023","journal-title":"JTO Clin. Res. Rep."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/568\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T04:28:22Z","timestamp":1760588902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/10\/568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,11]]},"references-count":47,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["curroncol32100568"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32100568","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,11]]}}}